Already competing to bring the first vaccine against respiratory syncytial virus (RSV) to market, Pfizer and GSK are also fighting a patent infringement battle in the courts.
Future booster campaigns against COVID-19 should include vaccines with a component targeting the Omicron variant of SARS-CoV-2, according to the FDA's Vaccines and Related Biological Produc
The latest start-up to emerge from the Roivant stable is named Priovant Therapeutics, and has been formed to develop a JAK1/TYK2 inhibitor originated by Pfizer as a treatment for autoimmune
US biotech Enanta Pharma has filed a lawsuit against Pfizer, claiming that its oral antiviral for COVID-19 Paxlovid infringes one of its patents and seeking damages from the pharma giant.
AbbVie has filed for approval of its oral CGRP inhibitor Qulipta for prevention of chronic migraine, seeking to leap ahead of its main rival in the class.
Dominance of the pneumococcal vaccine category is a race between Merck & Co and Pfizer, and while the latter is comfortably in front at the moment with its Prevnar franchise, Merck has
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.